Cellular mucosal defense is attenuated with chronicity of Helicobacter pylori infection.
Study Design
- نوع الدراسة
- Observational Study
- حجم العينة
- 44
- المجتمع المدروس
- 44 adult patients (16 H.pylori+) and 69 mice
- التدخل
- Cellular mucosal defense is attenuated with chronicity of Helicobacter pylori infection. N-acetylcysteine (in mouse experiments)
- المقارن
- H. pylori-infected vs uninfected
- النتيجة الأولية
- Mucosal antioxidant response
- اتجاه التأثير
- Negative
- خطر التحيز
- Moderate
Abstract
This study assessed the mucosal antioxidant response during acute (mouse) and chronic (adult human) H. pylori infection and following N-acetylcysteine administration. Antral biopsies were obtained from 44 patients (16 infected, 28 noninfected). Sixty-nine mice were sacrificed after 1 (n = 25), 4 (n = 28), or 6 (n = 16) months of infection. A further 29 mice received N-acetylcysteine or water (n = 21) for 14 days following 2.5 weeks of infection. Infected patients showed similar glutathione levels and G6PDH activity to noninfected subjects (P > 0.05). Myeloperoxidase activity was higher in infected patients (P < 0.05). In infected mice, glutathione levels and G6PDH activity were elevated at all time points up 6 months of infection (P < 0.05). Myeloperoxidase activity was increased in infected mice after 1 and 4 months (P < 0.05) but not at 6 months of infection (P > 0.05). N-Acetylcysteine reduced all three parameters in H. pylori-infected mice (P < 0.05). These results suggest an up-regulation of the antioxidant defense system during H. pylori infection in the mouse but not in humans. N-Acetylcysteine reduces the response during infection possibly by lowering the oxidant load.
باختصار
Results suggest an up-regulation of the antioxidant defense system during H. pylori infection in the mouse but not in humans and N-Acetylcysteine reduces the response during infection possibly by lowering the oxidant load.
Used In Evidence Reviews
Similar Papers
Digestion · 2016
Reduced Abundance of Butyrate-Producing Bacteria Species in the Fecal Microbial Community in Crohn's Disease.
Gut · 1996
Evaluating the antioxidant potential of new treatments for inflammatory bowel disease using a rat model of colitis.
Journal of nanobiotechnology · 2022
Oral administration of turmeric-derived exosome-like nanovesicles with anti-inflammatory and pro-resolving bioactions for murine colitis therapy.
Frontiers in endocrinology · 2024
The emerging role of oxidative stress in inflammatory bowel disease.
The British journal of nutrition · 2012
Omega-3 fatty acids and inflammatory bowel diseases - a systematic review.
Helicobacter · 2007